Advertisement
Product › Details
dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor)
Next higher product group | antidiabetic | |
Status | 2001-01-01 development existent | |
Organisation | Probiodrug Gesellschaft für Arzneimittelforschung mbH | |
Today | Vivoryon Therapeutics AG (Euronext Amsterdam: VVY) | |
Group | Vivoryon (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antidiabetic
- [1] Roche. (12/4/23). "Press Release: Roche Enters into a Definitive Merger Agreement to Acquire Carmot Therapeutics, including Three Clinical Stage Assets with Best-in-class Potential in Obesity and Diabetes". Basel....
- [2] Evolva Holding S.A.. (11/14/23). "Press Release: Evolva and Breko Broaden Partnership by Signing Agreement for the Exclusive Distribution of Veri-te Resveratrol in Germany, Austria, Thailand and Vietnam". Reinach....
- [3] AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]"....
- [4] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
- [5] Boehringer Ingelheim. (1/24/23). "Press Release: US FDA Accepts Supplemental New Drug Application for Jardiance for Adults with Chronic Kidney Disease". Ingelheim & Indianapolis, IN....
- [6] Minoryx Therapeutics S.L.. (5/31/22). "Press Release: Minoryx Raises €51 Million to Support Marketing Authorization Application and Launch Preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy". Mataró, Barcelona....
- [7] Pancryos ApS. (5/24/22). "Press Release: Pancryos Announces Exclusive Global License Agreement for First in Class Macroencapsulation Device". Copenhagen....
- [8] Zealand Pharma A/S. (3/30/22). "Press Release: Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations". Copenhagen & Boston, MA....
- [9] Enthera S.r.l.. (7/7/21). "Press Release: Enthera Pharmaceuticals Opens Early Drug Discovery Unit at OpenZone Life Sciences Campus to Expand Autoimmune Disease Research". Milan....
- [10] Enthera S.r.l.. (1/28/21). "Press Release: Enthera Pharmaceuticals Extends Series A Financing, Raising a Total of €35 million". Milan....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top